iShares International Treasury Bond ETF vs Novavax Inc — how do they compare? iShares International Treasury Bond ETF trades at $39.75 (market cap $1.30B), while Novavax Inc trades at $12.58 (market cap $1.82B). The key difference: Novavax Inc is the larger of the two by market cap, and Novavax Inc is trading nearer its 52-week high, iShares International Treasury Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares International Treasury Bond ETF for 92 Days and Novavax Inc for 59 Days on average.
| IGOV | NVAX | |
|---|---|---|
Market Cap | $1.30B | $1.82B |
Volume | 693,740 | 6,198,505 |
Sector | Fixed Income | Health |
52-Week High | $42.99 | $12.56 |
52-Week Low | $39.65 | $6.22 |
Typical Hold Time | 92 Days | 59 Days |
Enterprise Value | — | $1.39B |
Signals from Pluang's Aura AI — not financial advice
IGOV trades at $39.75 with minimal daily movement (+0.13%). Technical indicators show a bearish bias with moving averages signaling caution, though oscillators remain neutral. The stock faces significant resistance at $40 across multiple levels. Financial ratios are unavailable in current data, limiting fundamental assessment.
The stock's outlook remains cautious due to technical weakness and limited fundamental visibility. Rising bond yields create macroeconomic headwinds for equities, though inverse Treasury ETFs may benefit. Investors require updated financial disclosures to properly evaluate valuation and growth prospects amid current market volatility.
Novavax (NVAX) trades at $12.41, up 10.61% today, with strong technical momentum and bullish moving average signals. The company shows mixed fundamentals with a low P/E of 3.14 and EV/EBITDA of 1.72, but negative net income margin of -59.87% and negative shareholder equity. Recent earnings beats and FDA approvals for updated COVID-19 vaccines provide near-term catalysts.
Investment outlook remains speculative with significant execution risks despite analyst optimism (74% buy ratings). The company's pivot to Matrix-M adjuvant licensing and partnership model offers growth potential, but negative cash flow and high debt levels pose substantial financial risk. Stock appears undervalued on some metrics but requires careful risk management.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
The fund will invest at least 80% of its assets in the component securities of the underlying index and will invest at least 90% of its assets in fixed income securities included in the underlying index. The underlying index measures the performance of fixed-rate, local currency, investment-grade, sovereign bonds from certain developed markets. The fund is non-diversified.
Read more on IGOV →Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →